0001735726-21-000003.txt : 20211103 0001735726-21-000003.hdr.sgml : 20211103 20211102173704 ACCESSION NUMBER: 0001735726-21-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211102 EFFECTIVENESS DATE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OncoNano Medicine, Inc. CENTRAL INDEX KEY: 0001735726 IRS NUMBER: 811713330 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-378478 FILM NUMBER: 211372725 BUSINESS ADDRESS: STREET 1: 550 RESERVE STREET STREET 2: SUITE 190 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: (682) 712-1581 MAIL ADDRESS: STREET 1: 550 RESERVE STREET STREET 2: SUITE 190 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D/A 1 primary_doc.xml X0708 D/A LIVE 0001735726 OncoNano Medicine, Inc. 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 682.285.1411 DELAWARE None None Corporation true Martin Driscoll c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Director John Dyett c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Alvaro Guillem c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Matthew Head c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Yumin Qiu c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Biotechnology Decline to Disclose 06b true 0001735726-21-000002 2020-10-15 false true false 0 Salem Partners LLC 43363 None None 11111 Santa Monica Blvd., Suite 2250 Los Angeles CA CALIFORNIA 90025 AZ ARIZONA CA CALIFORNIA CO COLORADO FL FLORIDA IN INDIANA MA MASSACHUSETTS NV NEVADA NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OR OREGON PA PENNSYLVANIA TX TEXAS true 68407469 68407469 0 false 27 0 2458296 true The broker earned $2,458,296 in cash and a warrant to purchase 1,688,530 shares of common stock. 0 false OncoNano Medicine, Inc. /s/ Martin Driscoll Martin Driscoll CEO 2021-11-02